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Abstract
Past studies have shown that the inositol polyphosphate 5-phosphatase, phosphatidylinositol 4,5-bisphosphate
5-phosphatase (PIB5PA), is commonly downregulated or lost in melanomas, which contributes to elevated
activation of phosphatidylinositol 3-kinase (PI3K)/Akt in melanoma cells. In this report, we provide evidence that
PIB5PA deficiency plays a role in resistance of melanoma cells to RAF/mitogen-activated protein kinase kinase
(MEK) inhibitors. Ectopic expression of PIB5PA enhanced apoptosis induced by the RAF inhibitor PLX4720 in
BRAFV600E and by the MEK inhibitor U0126 in both BRAFV600E and wild-type BRAF melanoma cells. This was
due to inhibition of PI3K/Akt, as co-introduction of an active form of Akt (myr-Akt) abolished the effect of over-
expression of PIB5PA on apoptosis induced by PLX4720 or U0126. While overexpression of PIB5PA triggered
activation of Bad and down-regulation of Mcl-1, knockdown of Bad or overexpression of Mcl-1 recapitulated, at
least in part, the effect of myr-Akt, suggesting that regulation of Bad and Mcl-1 is involved in PIB5PA-mediated sen-
sitization ofmelanoma cells to the inhibitors. The role of PIB5PA deficiency in BRAF inhibitor resistancewas confirmed
by knockdown of PIB5PA, which led to increased growth of BRAFV600E melanoma cells selected for resistance to
PLX4720. Consistent with its role in vitro, overexpression of PIB5PA and the MEK inhibitor selumetinib cooperatively
inhibited melanoma tumor growth in a xenograft model. Taken together, these results identify loss of PIB5PA as a
novel resistance mechanism of melanoma to RAF/MEK inhibitors and suggest that restoration of PIB5PA may be a
useful strategy to improve the therapeutic efficacy of the inhibitors in the treatment of melanoma.
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Introduction
Aberrant activation of survival signaling pathways causes uncontrolled
proliferation and resistance to apoptosis and plays an important role
in cancer development, progression, and resistance to treatment [1,2].
In melanoma, activation of the mitogen-activated protein kinase path-
way stems primarily from activating mutations of BRAF with the
most common mutation being a glutamic acid for valine substitution
at position 600 (BRAFV600E) [3,4]. Targeting mutant BRAF using
small molecule inhibitors such as vemurafenib and dabrafenib has
achieved unprecedented responses in metastatic melanoma patients
[5–7]. However, complete remission is rare and a proportion of mutant
Address all correspondence to: Xu Dong Zhang, MD, PhD, The University of
Newcastle, LS3-49, Life Sciences Building, Newcastle, New South Wales 2308,
Australia. E-mail: Xu.Zhang@newcastle.edu.au or Lin Jie Zhang, MD, PhD, Depart-
ment of Immunology, Anhui Medical University, Anhui 230032, China. E-mail:
zlj33@ahmu.edu.cn or Sen Yang, MD, PhD, Institute of Dermatology and Department
of Dermatology, First Hospital of Anhui Medical University, Anhui 230032, China.
E-mail: Yangsen@medmail.com.cn
1This work was supported by research grants from the National Natural Science
Foundation (81071809), High Education Young Talents Foundation of Anhui Province
(2012SQRL069), China, and the NSW State Cancer Council, Cancer Institute NSW,
and the National Health and Medical Research Council, Australia. The authors have no
conflict of interest to declare.
2These authors contributed equally to this work.
Received 12 March 2013; Revised 7 May 2013; Accepted 9 May 2013
Copyright © 2013 Neoplasia Press, Inc.
1944-7124/13 DOI 10.1593/tlo.13277
www.transonc.com
Trans la t iona l Onco logy Volume 6 Number 4 August 2013 pp. 470–481 470
Open access under CC BY-NC-ND license.   
BRAF melanomas are less responsive to the inhibitors, indicative of
inherent resistance [5,8–10]. Moreover, durations of responses are
commonly limited with most patients relapsing within 1 year, indica-
tive of development of acquired drug resistance [5,8–10].
Multiple mechanisms have been shown to contribute to resistance of
mutant BRAF melanomas to BRAF inhibitors [5,8–10]. These include
those leading to insufficient inhibition of RAF/mitogen-activated
protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK)
signaling and those promoting melanoma cell survival and proliferation
alternative to the RAF/MEK/ERK pathway, such as increased activation
of the phosphatidylinositol 3-kinase (PI3K)/Akt or nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) pathway [11–19]. Indeed,
combinations of RAF inhibitors and inhibitors of MEK such as trametinib
to further inhibit MEK/ERK signaling have yielded promising results in
clinical trials [20–22]. Co-targeting the PI3K/Akt and RAF/MEK/ERK
pathways is also being evaluated in early clinical studies [17,23].
PI3K signaling is initiated with engagement of extracellular growth
factors to receptor tyrosine kinases. This results in recruitment of
PI3K to plasma membrane–anchored receptors where it is activated
leading to increases in the production of phosphatidylinositol 3,4-
bisphosphate and phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3),
which, in turn, bind to and activatemultiple downstream effectors [24–26].
Among them is Akt that is activated by two phosphorylation events at
Thr308 and Ser473 involving phosphoinositide-dependent kinases 1 and 2,
respectively [27,28]. While phosphorylation at the Thr308 partially acti-
vates Akt, its full activation requires phosphorylation at Ser473 [27–30].
The intracellular levels of PI(3,4,5)P3 are negatively regulated
through dephosphorylation by two classes of inositol polyphosphate
phosphatases [31,32]. The 3-phosphatase, phosphate and tensin
homolog deleted on chromosome 10 (PTEN), dephosphorylates
the 3-position of PI(3,4,5)P3 to generate phosphatidylinositol 4,5-
bisphosphate [33,34], whereas 5-phosphatases, such as Src homology
2–containing inositol 5-phosphatase, Src homology 2–containing
inositol 5-phosphatase 2, and phosphatidylinositol 4,5-bisphosphate
5-phosphatase (PIB5PA)/proline-rich inositol polyphosphate phospha-
tase, dephosphorylate the 5-position to produce phosphatidylinositol
3,4-bisphosphate [33]. The latter is, in turn, subjected to dephosphor-
ylation by inositol polyphosphate 4-phosphatase type I (INPP4A) and
type II (INPP4B) at the 4-position to terminate PI3K signaling [34–36].
Whereas PTEN is a well-established tumor suppressor [32,37], we have
recently shown that PIB5PA that is also commonly downregulated or
lost similarly plays an important role in negative regulation of PI3K/
Akt and has a tumor-suppressive role in melanoma [38].
In this study, we have examined the potential effect of PIB5PA
deficiency on sensitivity of melanoma cells to BRAF and MEK inhibi-
tors. We report here that introduction of exogenous PIB5PA sensitizes
melanoma cells to apoptosis induced by inhibition of RAF/MEK/ERK
signaling in vitro and in vivo and that this is due to inhibition of PI3K/
Akt signaling. In addition, we demonstrate that PIB5PA deficiency
contributes to growth of BRAFV600E melanoma cells selected for
resistance to PLX4720. These results suggest that restoration of PIB5PA
expression may be a useful strategy to improve the therapeutic efficacy
of RAF and MEK inhibitors in the treatment of melanoma.
Materials and Methods
Cell Culture, Reagents, and Antibodies
The human melanoma cell lines, ME1007, Mel-FH, MM200,
Mel-RMu, Mel-CV, and IgR3, which have been previously described,
were cultured in Dulbecco’s modified Eagle’s medium containing 5%
fetal calf serum [18]. ME1007 and Mel-FH harbor wild-type BRAF,
whereas MM200, Mel-RMu, Mel-CV, and IgR3 carry BRAFV600E.
PLX4720-resistant Mel-RMu.S andMel-CV.S sublines were generated
and maintained as reported before [18]. None of the cell lines harbors
activating mutations in PTEN, PIK3CA, BRAF, NRAS, KIT, and
EGFR (data not shown). All of them carry wild-type PIB5PA as shown
by analysis of all the 13 exons (including the intron/exon boundaries) of
the gene encoding PIB5PA, INPP5J (data not shown). The MEK
inhibitor U0126 was purchased from Promega (San Luis Obispo,
CA). The MEK inhibitor selumetinib (AZD6244; ARRY-142886)
and the BRAF inhibitor PLX4720 were purchased from Selleck
(Houston, TX). These inhibitors were dissolved in DMSO (Sigma-
Aldrich, Shanghai, China). The rabbit polyclonal antibody against
caspase-3 was from Stressgen (Farmingdale, NY). Antibodies against
PIB5PA, Mcl-1, pSer136-Bad, p-ERK1/2, Bcl-2, Bcl-XL, and Smac/
DIABLO were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Antibodies against pSer473-Akt, Akt, ERK1/2, Bad, and Puma
were from Cell Signaling Technology (Beverly, MA). Antibodies
against poly (ADP-ribose) polymerase (PARP) and cytochrome c were
from BD Pharmingen (North Ryde, NSW, Australia). Antibodies
against Bim and Noxa were from IMGENEX (Stepney, SA, Australia).
The mouse antibody against COX IV was from Clontech (Mountain
View, CA). The mouse monoclonal antibody against β-actin was
from Abcam (Cambridge, MA). The antibody against glyceraldehyde
3-phosphate dehydrogenase (GAPDH)was fromAmbion (Carlsbad,CA).
Establishment of Melanoma Cell Lines Carrying an
Inducible PIB5PA Expression System
A lentivirus-based inducible gene expression system described
previously was used to express PIB5PA conditionally in melanoma
cells [39]. Briefly, the system involves co-infection of two lentiviral
particles: one encoding the inducible transcriptional activator Gal4
1-147 ERT2VP16 (GEV16) cloned into pFU-GEV16-PGK-Hygro
containing a hygromycin B resistance gene, and another, PIB5PA
cDNA cloned into pF-5xUAS-SV40-puro containing a puromycin
resistance gene. Dual antibiotic selection was applied deriving a cell
population carrying both GEV16 and PIB5PA. Application of low
nM concentrations of 4-hydroxytestosterone (4-OHT) drives the
expression of PIB5PA. Two melanoma cell lines (ME1007 and
Mel-FH) were used to establish sublines carrying inducible exogenous
PIB5PA (ME1007.PIB5PA and Mel-FH.PIB5PA).
Melanoma Xenograft Mouse Model
Viable ME1007.PIB5PA cells (1 × 107 cells per mouse) with or
without pretreatment with 4-OHT (10 nM) for 36 hours were injected
subcutaneously into right posterior flanks of nu/nu mice (Shanghai
SLAC Laboratory, Shanghai, China). Mice were then randomly
assigned into four groups (n = 6 for each group) that were, respectively,
treated with DMSO, selumetinib (25 mg/kg), 4-OHT (10 nM/g), and
4-OHTplus selumetinib through intraperitoneal injection every 3 days.
Tumor volumes were monitored using an electronic caliper twice per
week and calculated using the following formula: tumor volume
(mm3) = 0.5 × tumor length (mm) × tumor width2 (mm2). Mice were
sacrificed and tumors were weighed at day 36 after melanoma cell injec-
tion. Studies on animals were approved by the Animal Research Ethics
Committee of Anhui Medical University of China.
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Western Blot Analysis
Cells were harvested by trypsinization and washed with phosphate-
buffered saline, then disrupted on ice for 30 minutes in NP-40 lysis
buffer and cleared by centrifugation as previously described [18]. Equal
amounts of protein (30 μg) in cell lysate were separated by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis, transferred to mem-
branes, immunoblotted with specific primary and secondary anti-
bodies, and detected by Immun-Star HRP Chemiluminescent Kit.
The images were captured and the intensity of the bands was quanti-
tated using the Bio-Rad VersaDoc image system (Bio-Rad, Gladesville,
NSW, Australia).
CellTiter-Glo Assays
The CellTiter-Glo Assay was performed with the CellTiter-Glo
Luminescent Cell Viability Assay kit according to the manufacturer’s
instructions (Promega). Luminescence was recorded by Synergy 2
multi-detection microplate reader (Bio-Tek, Winooski, VT).
Apoptosis
Quantitation of apoptotic cells was carried out by measurement of
sub-G1 DNA content using propidium iodide in a flow cytometer as
described elsewhere [18]. In brief, cells were seeded at 1 × 105/well
onto 24-well culture plates and allowed to grow for 24 hours followed
by the desired treatment. Cells were harvested with propidium iodide
buffer, transferred to fluorescence-activated cell sorting (FACS) tubes,
and incubated overnight at 4°C in the dark before analysis.
BrdU Proliferation Assays
5-Bromo-2′-deoxyuridine (BrdU) cell proliferation assays were
carried out using an assay kit (Cell Signaling Technology) as per the
manufacturer’s instructions. Briefly, cells were seeded at 5 × 103/well in
96-well plates overnight before treatment as desired. BrdU (10 mM)
was added and cells were incubated for 4 hours before BrdU assays were
carried out. Absorbance was read at 450 nm using a Synergy 2 multi-
detection microplate reader (Bio-Tek).
Clonogenic Assays
Cells were seeded at 2000/well onto six-well culture plates and
allowed to grow for 24 hours followed by the desired treatment. Cells
were then allowed to grow for another 12 days before fixation with
methanol and staining with crystal violet.
Preparation of Mitochondrial and Cytosolic Fractions
The mitochondrial and cytosolic fractions were prepared by using
the Qproteome Mitochondrion Isolation Kit (Qiagen, Doncaster,
Australia) according to the manufacturer’s instruction. In brief, after
trypsinization, cells were washed with phosphate-buffered saline
followed with 0.9% sodium chloride solution. Cell pellets were
resuspended in ice-cold lysis buffer and incubated for 10 minutes at
4°C on an end-over-end shaker. Cell lysates were then spun at 1000 g
for 10 minutes at 4°C and resulting supernatants were collected as
cytosolic fractions.
Plasmid Vectors and Transfection
The pCGN-PIB5PA-human influenza hemagglutinin (HA) con-
struct was a generous gift from Christina A. Mitchell (Monash Uni-
versity, Victoria, Australia). The pcDNA-myr-HA-Akt construct was
purchased from Addgene (Cambridge, MA; Plasmid 9017). The
pcDNA–Mcl-1–flag construct was provided by Professor Mian Wu
from the University of Science and Technology of China. Cells were
transfected with 2 μg of plasmid as well as the empty vector in Opti-
MEM medium (Invitrogen, Shanghai, China) with Lipofectamine
2000 reagent (Invitrogen) according to the manufacturer’s protocol.
Small Interfering RNA
Transfection of small interfering RNA (siRNA) pools was carried out
as described previously [18].Melanoma cells were seeded at 1 × 105 cells
per well in 24-well plates and allowed to reach 50% confluence on
the day of transfection. The siRNA constructs for Bad and PIB5PA
were obtained as the siGENOMESMARTpool reagents (Dharmacon,
Lafayette, CO), the siGENOMESMARTpoolBad (M-003870-02-
0010) and the siGENOME SMARTpool PIB5PA (M-009108-01-
0010). The non-targeting siRNA control, SiConTRol–Non-targeting
siRNA pool (D-001206-13-20), was also obtained from Dharmacon.
Cells were transfected with 50 nM/l siRNA in Opti-MEM medium
(Invitrogen) using Lipofectamine 2000 reagent (Invitrogen) according
to the manufacturer’s transfection protocol.
Statistical Analysis
The significance of differences between experimental data was
determined with the two-tailed Student’s t test for unpaired observa-
tions using SPSS 11.0 (SPSS, Chicago, IL) software. A P value < .05
was considered statistically significant.
Results
Wild-type BRAF Melanoma Cells Overexpressing PIB5PA
Are More Susceptible to Apoptosis Induced by the
MEK Inhibitor U0126
To study the impact of PIB5PA on sensitivity of melanoma cells
to inhibition of the MEK/ERK pathway, we took advantage of two
melanoma sublines (ME1007.PIB5PA and Mel-FH.PIB5PA) condi-
tionally expressing PIB5PA in response to 4-OHT that were estab-
lished by transduction of a lentivirus-based inducible gene expression
system as described previously (Figure 1A) [38]. These cell lines and
their corresponding parental counterparts (ME1007 and Mel-FH,
respectively) harbored wild-type BRAF. As reported before, 4-OHT
inhibited viability of ME1007.PIB5PA and Mel-FH.PIB5PA cells as
measured by CellTiter-Glo assays but did not impinge on survival of
ME1007 and Mel-FH cells (Figure 1B) [38]. However, the MEK
inhibitor U0126 triggered moderate inhibition of cell viability in both
ME1007.PIB5PA and Mel-FH.PIB5PA and ME1007 and Mel-FH
cells (Figure 1B). Although the combination of U0126 and 4-OHT
did not increase the inhibitory effect on cell survival in ME1007 and
Mel-FH cells in comparison with treatment with U0126 alone, it
markedly enhanced the inhibitory effect on survival of ME1007.PIB5-
PA andMel-FH.PIB5PA cells (P < .01, two-tailed Student’s t test). The
enhanced effect of the combination of U0126 and 4-OHT on viability
of these cells was also reflected by reduced clonogenicity (Figure 1C).
We examined if induction of apoptosis was involved in increased
inhibition of cell viability by the combination of U0126 and 4-OHT.
As shown in Figure 1D, U0126 induced moderate levels of apoptosis in
ME1007.PIB5PA and Mel-FH.PIB5PA and ME1007 and Mel-FH
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Figure 1. Overexpression of PIB5PA sensitizes wild-type BRAF melanoma cells to the MEK inhibitor U0126. (A) Whole-cell lysates from
ME1007.PIB5PA and Mel-FH.PIB5PA cells treated with 4-OHT (10 nM) for 24 hours were subjected to Western blot analysis. The data
shown are representative of three individual experiments. (B) ME1007, Mel-FH, ME1007.PIB5PA, and Mel-FH.PIB5PA cells treated with
4-OHT (10 nM), U0126 (20 μM), or the combination of both for 48 hours were subjected to measurement of cell viability using CellTiter-
Glo assays. The relative cell viability of cells without any treatment was arbitrarily designated as 100%. The data shown are means ±
SEM of three individual experiments. (C) Mel-FH.PIB5PA and ME1007.PIB5PA cells were seeded onto six-well plates at 2000 cells/well in
medium with or without 4-OHT (10 nM), U0126 (20 μM), or the combination of both. Cells were allowed to grow for 12 days before being
fixedwithmethanol and stainedwith crystal violet. Data shownare representative of three individual experiments. Scale bar, 1 cm. (D)Mel-FH.
PIB5PA, ME1007.PIB5PA, and their corresponding parental cells were treated with 4-OHT (10 nM), U0126 (20 μM), or the combination of
both for 48 hours. Apoptotic cells were quantitated by measurement of sub-G1 DNA content. The data shown are means ± SEM of
three individual experiments. (E) Whole-cell lysates from ME1007.PIB5PA and Mel-FH.PIB5PA cells treated with 4-OHT (10 nM), U0126
(20 μM), or the combination of both for 24 hours were subjected to Western blot analysis. The data shown are representative of three
individual experiments.
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cells, whereas 4-OHT similarly induced low levels of apoptosis in
ME1007.PIB5PA and Mel-FH.PIB5PA but not in ME1007 and
Mel-FH cells. Co-treatment with U0126 and 4-OHT significantly
enhanced induction of apoptosis in ME1007.PIB5PA and Mel-FH.
PIB5PA cells (P < .01, two-tailed Student’s t test), which was confirmed
by increased activation of caspase-3 and cleavage of its substrate PARP
(Figure 1E). However, it did not increase apoptosis in ME1007 and
Mel-FH cells compared with treatment with U0126 alone (Figure 1D).
The inhibitory effect of U0126 on the MEK/ERK pathway was
corroborated by reduced phosphorylation of ERK1/2 (Figure 1E) and
the inhibitory effect of 4-OHT on PI3K/Akt signaling in ME1007.
PIB5PA and Mel-FH.PIB5PA by reduction in phosphorylation of
Akt (Figure 1A).
Overexpression of PIB5PA Sensitizes BRAFV600E Melanoma
Cells to Apoptosis Induced by Either the RAF Inhibitor
PLX4720 or the MEK Inhibitor U0126
We next examined whether overexpression of PIB5PA impacts on
sensitivity of BRAFV600E melanoma cells to apoptosis induced by the
RAF inhibitor PLX4720. To this end, we transiently introduced an
HA-tagged PIB5PA construct into IgR3 andMM200, two BRAFV600E
melanoma cell lines that were relatively resistant to apoptosis induced
by the RAF inhibitor PLX4720 (Figure 2A). Overexpression of
PIB5PA only causedmoderate levels of apoptosis (<20% apoptotic cells),
consistent with previous findings (Figure 2, B and C) [38]. However, it
sensitized both IgR3 and MM200 cells to PLX4720-induced apoptosis
(Figure 2B). Similarly, it enhanced sensitivity of the cells to apoptosis
induced by the MEK inhibitor U0126 (Figure 2C ). The inhibitory
effects of overexpression of PIB5PA and PLX4720 on activation of
Akt and ERK were shown in Figure 2, A and D, respectively. Taken
together, these results indicate that PIB5PA sensitizes melanoma cells
to apoptosis induced by inhibition of MEK/ERK signaling.
PIB5PA-mediated Sensitization of Melanoma Cells to RAF and
MEK Inhibitors Is due to Its Inhibitory Effect on PI3K/Akt
Because overexpression of PIB5PA inhibited activation of Akt
(Figures 1A and 2A) [38], we examined whether this is causative
for its effect on sensitivity of melanoma cells to apoptosis induced
by inhibition of MEK/ERK signaling. To do so, we introduced an
active form of Akt (myr-Akt) into Mel-FH.PIB5PA and ME1007.
PIB5PA cells (Figure 3A) [40]. As shown in Figure 3B, myr-Akt
efficiently reversed 4-OHT–triggered enhancement of apoptosis
Figure 2. Overexpression of PIB5PA sensitizes BRAFV600E melanoma cells to the RAF inhibitor PLX4720 or the MEK inhibitor U0126.
(A) IgR3 and MM200 cells were transiently transfected with empty HA or PIB5PA-HA construct. Twenty-four hours later, whole-cell
lysates were subjected to Western blot analysis. The data shown are representative of three individual experiments. (B) IgR3 and
MM200 cells were transiently transfected with empty HA or PIB5PA-HA construct. Twenty-four hours later, cells were treated with
PLX4720 (5 μM) for a further 48 hours. Apoptotic cells were quantitated by measurement of sub-G1 DNA content. The data shown
are means ± SEM of three apoptotic assays. (C) IgR3 and MM200 cells were transiently transfected with empty HA or PIB5PA-HA
construct. Twenty-four hours later, cells were treated with U0126 (20 μM) for a further 48 hours. Apoptotic cells were quantitated by
measurement of sub-G1 DNA content. The data shown are means ± SEM of three apoptotic assays. (D) Whole-cell lysates from IgR3
and MM200 cells transfected with empty HA or PIB5PA-HA with or without treatment with PLX4720 (5 μM) for 24 hours were subjected
to Western blot analysis. The data shown are representative of three individual experiments.
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induced by U0126. Similarly, co-introduction of myr-Akt and PIB5PA
into IgR3 and MM200 cells markedly reduced the sensitizing effect of
PIB5PA on PLX4720-induced apoptosis (Figure 3, C and D). These
results indicate that the effect of overexpression of PIB5PA on melanoma
cell survival is mediated by its inhibitory effect on PI3K/Akt signaling.
Sensitization of Melanoma Cells to Apoptosis Induced by
Inhibition of MEK/ERK Signaling Is Inhibitable by Mcl-1
Both PLX4720 and U0126 induce apoptosis of melanoma cells by
activation of the mitochondrial apoptotic pathway [41,42]. Consistent
with this, while co-treatment of ME1007.PIB5PA cells with U0126 in
the presence of 4-OHT resulted in increased mitochondrial release of
cytochrome c and Smac/DIABLO into the cytosol, transient over-
expression of PIB5PA similarly caused increases in release of these
mitochondrial apoptogenic proteins in IgR3 cells (Figure 4A), suggest-
ing that the mitochondrial apoptotic pathway is involved in PIB5PA-
mediated sensitization of melanoma cells to apoptosis induced by
inhibition of MEK/ERK. Indeed, overexpression of Mcl-1 in
ME1007.PIB5PA cells markedly inhibited apoptosis induced by
U0126 in the absence or presence of 4-OHT (P < .01, two-tailed
Student’s t test; Figure 4B). Consistently, the sensitizing effect of over-
expression of PIB5PA on IgR3 cells to PLX4720-induced apoptosis
was significantly blocked when exogenous Mcl-1 was co-introduced
(Figure 4C ). These results indicate that the mitochondrial apoptotic
pathway is essential for PIB5PA-mediated sensitization of melanoma
cells to apoptosis induced by inhibition of MEK/ERK signaling.
Figure 3.Myr-Akt reverses the sensitizing effect of overexpression of PIB5PA on apoptosis induced by PLX4720 or U0126. (A) ME1007.
PIB5PA and Mel-FH.PIB5PA cells were transiently transfected with vector alone or an myr-Akt construct. Twenty-four hours later, cells
were treated with 4-OHT (10 nM) for a further 24 hours. Whole-cell lysates were subjected to Western blot analysis. The data shown
are representative of three individual experiments. (B) ME1007.PIB5PA and Mel-FH.PIB5PA cells were transiently transfected with
vector alone or an myr-Akt construct. Twenty-four hours later, cells were treated with 4-OHT (10 nM), U0126 (20 μM), or 4-OHT plus
U0126 for a further 48 hours. Apoptotic cells were quantitated by measurement of sub-G1 DNA content. The data shown are means ±
SEM of three apoptotic assays. (C) IgR3 and MM200 cells were transiently transfected with vector alone or an myr-Akt construct with
or without co-transfection with empty HA or PIB5PA-HA. Twenty-four hours later, whole-cell lysates were subjected to Western blot
analysis. The data shown are representative of three individual experiments. (D) IgR3 and MM200 cells were transiently transfected with
vector alone or an myr-Akt construct with or without co-transfection with empty HA or PIB5PA-HA. Twenty-four hours later, cells were
treated with PLX4720 (5 μM) for a further 48 hours. Apoptotic cells were quantitated by measurement of sub-G1 DNA content. The data
shown are means ± SEM of three apoptotic assays.
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Figure 4. Overexpression of Mcl-1 blocks PIB5PA-mediated sensitization of melanoma cells to apoptosis induced by PLX4720 or U0126.
(A) Left panel: Cytosolic (Cyto.) andmitochondrial (Mito.) fractions fromME1007.PIB5PA cells with orwithout treatment with 4-OHT (10 nM),
U0126 (20 μM), or the combination of both for 36 hours were subjected to Western blot analysis. Right panel: Cytosolic (Cyto.) and
mitochondrial (Mito.) fractions from IgR3 cells transfected with empty HA or PIB5PA constructs followed by treatment with PLX4720
(5 μM) for 36 hours were subjected to Western blot analysis. Western blot analyses of the expression of β-actin and COXIV were included
for control of the relative purity of cytosolic and mitochondrial fractions. The data shown are representative of three individual experiments.
(B) Left panel: ME1007.PIB5PA cells were transfected with empty flag or an Mcl-1–flag construct. Twenty-four hours later, cells were
treated with 4-OHT (10 nM) for a further 24 hours. Whole-cell lysates were subjected to Western blot analysis. The data shown are rep-
resentative of three individual experiments. Right panel: ME1007.PIB5PA cells were transfected with empty flag or an Mcl-1–flag construct.
Twenty-four hours later, cells were treated with 4-OHT (10 nM), U0126 (20 μM), or the combination of both for 48 hours. Apoptotic cells
were quantitated bymeasurement of sub-G1 DNA content. The data shown aremeans± SEMof three apoptotic assays. (C) Left panel: IgR3
cells were transiently transfected with empty flag or an Mcl-1–flag construct with or without co-transfection with empty HA or PIB5PA-HA.
Twenty-four hours later, whole-cell lysates were subjected to Western blot analysis. The data shown are representative of three individual
experiments. Right panel: IgR3 cells were transiently transfected with empty flag or an Mcl-1–flag construct with or without co-transfection
with empty HA or PIB5PA-HA construct. Twenty-four hours later, cells were treated with PLX4720 (5 μM) for 48 hours. Apoptotic cells were
quantitated by measurement of sub-G1 DNA content. The data shown are means ± SEM of three apoptotic assays.
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Bad Plays an Important Role in PIB5PA-Mediated Sensitization
of Melanoma Cells to Apoptosis Induced by Inhibition of
MEK/ERK Signaling
To further study the mechanism by which overexpression of PIB5PA
enhances apoptosis induced by inhibition ofMEK/ERK signaling, we ex-
amined the expression of Bcl-2 family proteins in ME1007.PIB5PA cells
with or without exposure to 4-OHT and in IgR3 cells introduced with
exogenous PIB5PA in comparisonwith those transfectedwith vector-HA.
As shown in Figure 5A, overexpression of PIB5PA downregulated Mcl-1
and reduced the levels of phosphorylated Bad. In contrast, the expression
levels of Bcl-2, Bcl-XL, Bim, PUMA, and Noxa remained unaltered in
PIB5PA-overexpressing cells compared with corresponding control cells.
Figure 5. Knockdown of Bad blocks PIB5PA-mediated sensitization of melanoma cells to apoptosis induced by PLX4720 or U0126. (A)
Whole-cell lysates of ME1007.PIB5PA cells with or without treatment with 4-OHT (10 nM) for 24 hours (left panel) and IgR3 cells trans-
fected with the vector control or the PIB5PA-HA construct for 24 hours (right panel) were subjected to Western blot analysis. The data
shown are representative of three individual experiments. (B) Upper panel: ME1007.PIB5PA cells were transfected with the control or
Bad siRNA. Twenty-four hours later, cells were treated with 4-OHT (10 nM) for a further 24 hours. Whole-cell lysates were subjected to
Western blot analysis. Lower panel: IgR3 cells were transfected with empty HA or PIB5PA-HA construct with or without co-transfection
with the control or Bad siRNA. Twenty-four hours later, whole-cell lysates were subjected to Western blot analysis. The data shown are
representative of three individual experiments. (C) ME1007.PIB5PA cells were transfected with the control or Bad siRNA. Twenty-four
hours later, cells were treated with 4-OHT (10 nM), U0126 (20 μM), or the combination of both for 48 hours. Apoptotic cells were quan-
titated by measurement of sub-G1 DNA content. The data shown are means ± SEM of three apoptotic assays. (D) IgR3 cells were
transfected with empty HA or PIB5PA-HA construct with or without co-transfection with the control or Bad siRNA. Twenty-four hours
later, cells were treated with PLX4720 (5 μM) for 48 hours. Apoptotic cells were quantitated by measurement of sub-G1 DNA content.
The data shown are means ± SEM of three apoptotic assays.
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Down-regulation of phosphorylated Bad by overexpression of
PIB5PA suggests that it may play a role in PIB5PA-mediated sensi-
tization of melanoma cells to apoptosis induced by inhibition of
RAF or MEK. To verify this, we knocked down Bad by siRNA in
ME1007.PIB5PA and IgR3 cells (Figure 5B). siRNA inhibition of
Bad not only inhibited apoptosis induced by PIB5PA alone in both
cell lines but also markedly attenuated PIB5PA-mediated sensitiza-
tion to U0126-induced apoptosis in ME1007 cells and PLX4720-
induced apoptosis in IgR3 cells (P < .01, two-tailed Student’s t test;
Figure 5, C and D).
Figure 6. Induction of PIB5PA combined with the MEK inhibitor selumetinib cooperatively inhibited tumor growth in melanoma xeno-
graft model. (A) Viable ME1007.PIB5PA cells (1 × 107) with or without pretreatment with 4-OHT (10 nM) for 36 hours were subcutane-
ously injected into flanks of nu/numice. Two days later, mice were administered with either vehicle (DMSO; n= 6), 4-OHT (10 nM/g; n= 6),
selumetinib (25mg/kg; n=6), or the combination of 4-OHT and selumetinib through intraperitoneal injections every 3 days. Micewere killed
and tumor was harvested at 36 days after melanoma cell injection. Data shown are representative tumors in each group. Scale bars, 5 mm.
(B) Comparison of weight of tumors from animals treated with the vehicle control, 4-OHT, selumetinib, and the combination of 4-OHT and
selumetinib. The data shown are means ± SEM of 12 tumors (2 tumors in each mouse). (C) Comparison of growth rates of melanoma
xenografts in mice treated with the vehicle control, 4-OHT, selumetinib, and the combination of 4-OHT and selumetinib. The data shown
aremeans± SEM of 12 tumors (2 tumors in eachmouse). (D)Whole-cell lysates of crude tumor tissues from tumors generated byME1007.
PIB5PA cells with or without treatment with 4-OHT, selumetinib, or the combination of 4-OHT and selumetinib were subjected to Western
blot analysis. The data shown are representative of 12 tumors (2 tumors in each mouse).
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Overexpression of PIB5PA in Combination with the MEK
Inhibitor Selumetinib Enhances the Inhibitory Effect on
Melanoma Growth in a Xenograft Mouse Model
Overexpression of PIB5PA is known to reduce melanoma xeno-
graft growth in immunodeficient mice [38]. The MEK inhibitor
selumetinib also inhibits melanoma growth in mouse models [43].
We examined whether the combination of overexpression of PIB5PA
and selumetinib further enhance the inhibitory effect in vivo. To this
end, tumor growth of ME1007.PIB5PA cells subcutaneously trans-
planted into nu/nu mice treated with the vehicle control, 4-OHT,
selumetinib, or the combination of 4-OHT and selumetinib was exam-
ined. Although treatment with 4-OHT and, to a lesser extent, treat-
ment with selumetinib reduced melanoma growth in vivo (Figure 6,
A–C ), the combination of both resulted in significantly greater inhibi-
tion of tumor growth (Figure 6, A–C). This was associated with induc-
tion of PIB5PA, suppression of activation of Akt, down-regulation of
Mcl-1 and phosphorylated Bad, and activation of caspase-3 as shown
by examination of tumors from postmortem animals (Figure 6D).
PIB5PA Deficiency Contributes to Growth of BRAFV600E
Melanoma Cells Selected for Resistance to PLX4720
To obtain more direct evidence that PIB5PA deficiency contributes
to resistance of BRAFV600E melanoma cells to BRAF inhibitors, we
knocked down PIB5PA in two PLX4720-resistant melanoma sublines
(Mel-RMu.S and Mel-CV.S) that were established by prolonged
exposure of their parental counterparts (Mel-RMu and Mel-CV,
respectively) to the inhibitor [18]. Similar to their parental cells,
Mel-RMu.S and Mel-CV.S cells expressed low but detectable levels
of PIB5PA (Figure 7A). siRNA knockdown of PIB5PA resulted in
Figure 7. Knockdown of PIB5PA promotes growth of BRAFV600E melanoma cells selected for resistance to PLX4720. (A) PLX4720-
resistant Mel-RMu.S and Mel-CV.S cells and their parental counterparts, Mel-RMu and Mel-CV cells, were transfected with the control
or PIB5PA siRNA. Twenty-four hours later, whole-cell lysates were subjected to Western blot analysis of PIB5PA, pSer473-Akt, Akt, and
GAPDH (as a loading control). The data shown are representative of three individual Western blot analyses. (B) Mel-RMu.S and Mel-CV.S
cells were transfected with the control or PIB5PA siRNA. Seventy-two hours later, cells were subjected to proliferation assays using
the BrdU incorporation method. The data shown are means ± SEM of three individual BrdU incorporation assays. (C) Mel-RMu.S and
Mel-CV.S cells were transfected with the control or PIB5PA siRNA. Twenty-four hours later, viable cells were reseeded onto six-well
plates at 2000 cells/well in medium containing PLX4720 (5 μM). Cells were allowed to grow for 12 days before being fixed with methanol
and stained with crystal violet. Data shown are representative of three individual clonogenic assays. Scale bar, 1 cm. (D) Mel-RMu and
Mel-CV cells were transfected with the control or PIB5PA siRNA. Twenty-four hours later, cells were treated with PLX4720 (5 μM) for
another 72 hours. Cell viability was measured using CellTiter-Glo assays. The relative cell viability of cells of each cell line transfected
with the control siRNA without treatment with PLX4720 was arbitrarily designated as 100%. The data shown are means ± SEM of
three individual CellTiter-Glo assays.
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increased proliferation of Mel-RMu.S andMel-CV.S cells as shown in
BrdU incorporation and clonogenic assays (Figure 7, B and C ) and, as
expected, reduced sensitivity of Mel-RMu and Mel-CV to PLX4720
(Figure 7D). This was associated with increased activation of Akt
(Figure 7A). These results consolidate the role of PIB5PA in regulat-
ing sensitivity of BRAFV600E melanoma cells to BRAF inhibitors.
Discussion
In this report, we present evidence that loss of the 5-phosphatase
PIB5PA plays an important role in resistance of melanoma cells to
inhibition of the RAF/MEK/ERK pathway. While its expression is
commonly reduced or lost in melanoma cells in vitro and in vivo
[38], introduction of exogenous PIB5PA resulted in enhanced induc-
tion of apoptosis by the RAF inhibitor PLX4720 in BRAFV600E
melanoma cells and by the MEK inhibitor U0126 in both BRAFV600E
and wild-type BRAF melanoma cells and enhanced the therapeutic
efficacy of the MEK inhibitor selumetinib in a melanoma xeno-
graft mouse model. Moreover, we show that inhibition of PIB5PA
enhances growth of BRAFV600E melanoma cells selected for resistance
to PLX4720.
Inhibition of RAF/MEK/ERK signaling constrains melanoma cell
proliferation and induces apoptosis [4,7,10]. However, previous
studies have suggested a determining role of sensitivity to induction
of apoptosis in long-term responses of melanoma cells to BRAF or
MEK inhibitors [18]. Killing of cells occurred at early stages after
exposure of sensitive BRAFV600E melanoma cells to PLX4720, but
the remaining cells retained low proliferation potential even in the
presence of the inhibitor and regained high growth rate after it was
withdrawn [18]. This mirrors closely the clinical observation that
mutant BRAF melanomas frequently regress in response to BRAF
inhibitors but recur within relatively short periods [5–7]. Overcoming
resistance of melanoma cells to apoptosis appears therefore imperative
in improving therapeutic efficacy of RAF and MEK inhibitors.
Many mechanisms have been reported to be involved in resistance
of melanoma cells to inhibition of the RAF/MEK/ERK pathway
[5,8–10]. Among them, activation of the PI3K/Akt pathway is of
particular importance, in that PI3K/Akt signaling has been shown
to cooperate with mutant BRAF in melanomagenesis using in vivo
models and that melanoma cells resistant to RAF inhibitors display
increased activation of PI3K/Akt [18]. In addition, loss of PTEN
that negatively regulates PI3K/Akt confers resistance of melanoma
cells to BRAF inhibitors and cooperates with BRAFV600E to induce
metastatic melanoma [16].
We have recently shown that, similar to PTEN, the 5-phosphatase
PIB5PA is frequently lost in melanoma cells and has an important
role in inhibiting PI3K/Akt signaling and in suppressing melanoma
cell proliferation [38]. In this study, loss of PIB5PA was found to
similarly play a role in regulating sensitivity of melanoma cells to
apoptosis induced by inhibition of the RAF/MEK/ERK pathway,
in that introduction of exogenous PIB5PA sensitized melanoma cells
to apoptosis induced by the RAF inhibitor PLX4720 in BRAFV600E
melanoma cells and by the MEK inhibitor selumetinib in both
BRAFV600E and wild-type BRAFmelanoma cells. This sensitizing effect
was due to the inhibitory effect of PIB5PA on PI3K/Akt signaling, as
co-introduction of myr-Akt effectively reduced apoptosis induced by
PLX4720 or U0126 in melanoma cells overexpressing PIB5PA.
Activation of the BH3-only protein Bad and down-regulation of
Mcl-1 appeared to play important roles in PIB5PA-mediated sensi-
tization of melanoma cells to apoptosis induced by inhibition of RAF/
MEK/ERK signaling, in that introduction of exogenous PIB5PA
resulted in reduction in phosphorylation of Bad and decreases in
Mcl-1 and that siRNA knockdown of Bad or overexpression of
Mcl-1 inhibited the sensitization. Since induction of apoptosis by
RAF or MEK inhibitors is known to be mediated by activation of
the BH3-only protein Bim and down-regulation of Mcl-1 [41,42],
it is conceivable that Bad and Bim may cooperatively attenuate
anti-apoptotic Bcl-2 family proteins such as Mcl-1. The latter may
be further downregulated by RAF or MEK inhibitors in melanoma
cells overexpressing PIB5PA. Bad is well documented to be a down-
stream phosphorylation target of Akt, whereas Mcl-1 is also known to
subject to regulation by Akt signaling [44,45].
The PI3K/Akt pathway can also negatively regulate the expression
of Bim through a FOXO3a-mediated transcriptional mechanism
[16]. Consistently, resistance of melanoma cells to RAF inhibitors
mediated by loss of PTEN has been shown to be due to suppression
of Bim [16]. However, we did not observe any significant change in
the Bim expression in melanoma cells overexpressing PIB5PA com-
pared to corresponding controls. The reason for this discrepancy
remains unknown, but it is likely to be related to the variations in
cell lines used in the different studies. Regardless, our results clearly
demonstrated a protective role of loss of PIB5PA in melanoma cells
when the RAF/MEK/ERK pathway is inhibited.
An important finding of this study was that the combination of
exogenous PIB5PA and the MEK inhibitor selumetinib cooperatively
induced apoptosis and inhibited melanoma xenograft growth in vivo.
This supports the notion that restoration of the expression of PIB5PA
may be a useful strategy to improve the therapeutic efficacy of inhib-
itors of the RAF/MEK/ERK pathway in the treatment of melanoma.
However, since the majority of melanoma cell lines and fresh mela-
noma isolates expressed low levels of PIB5PA [38], it remains
unknown whether sensitivity of melanoma to RAF and MEK inhibi-
tors correlates in general with PIB5PA expression levels. Regardless,
our results showing that knockdown of PIB5PA promoted survival
and growth of BRAFV600E melanoma cells selected for resistance to
PLX4720 provided direct evidence that loss of PIB5PA plays a role
in resistance of melanoma cells to inhibition of the RAF/MEK/
ERK pathway. Studies using melanoma tissue samples from patients
with different responses to RAF or MEK inhibitors are warranted to
further clarify the role of loss of PIB5PA in resistance of melanoma to
the inhibitors.
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Table W2. QPCR Primer Sequences.
Gene Forward Primer (5′–3′) Reverse Primer (5′–3′) Assay Efficiency
UBC ATTTGGGTCGCGGTTCTTG TGCCTTGACATTCTCGATGGT 0.94
SDHA TGGGAACAAGAGGGCATCTG CCACCACTGCATCAAATTCAT 0.95
YWHAZ ACTTTTGGTACATTGTGGCTTCAA CCGCCAGGACAAAACAGTAT 0.89
DKC1 GGACGGCATTGAGGTCAATC ATGGTCGCAGGTAGAGATGA 0.91
GAR1 GGTGAGAAAGGACCTCCAAGAG CTGAAACCACCACCTCTTCCTC 0.96
NHP2 CCTCACGCGGAAGCTCTACAAA CAGTGTGTCTCCTGCCAAAACC 0.86
TERC CGCTGTTTTTCTCGCTGACTT TGCTCTAGAATGAACGGTGGAA 0.85
TERT TGACACCTCACCTCACCCAC CACTGTCTTCCGCAAGTTCAC 0.86
Figure W1. snoRNP signature score prognostic value is independent of MYC pathway activity and TERT expression. (A and B) Kaplan-
Meier analyses and corresponding log-rank P values for EFS in stage 4 patients according to snoRNP signature score. Group divisions
decided by median snoRNP score (HIGH, above median; LOW, below median). Analyses were performed in the Oberthuer 251-tumor
data set (A) and the Versteeg 88-tumor data set (B). (C and D) Multivariate Cox regression analysis including snoRNP score, MYCN
amplification status, MYC pathway activity, and TERT mRNA expression. Accompanying HRs (Exp(B)) with 95% CIs and significance
values are provided. Analyses were performed in the Oberthuer 251-tumor data set (C) and the Versteeg 88-tumor data set (D).
Table W1. Probe and Primer Sequences Used in CIMP Analyses of the Colorectal Tumors Using Methylight according to the Protocol Published by Weisenberger et al..
Gene Probe Forward Primer Reverse Primer
Calcium channel, voltage-dependent,
alpha 1G subunit
6FAM-AAATAACGCCGAATC
CGACAACCGA-BHQ-1
TTTTTTCGTTTCGCGTTTAGGT CTCGAAACGACTTCGCCG
Insulin-like growth factor 2 (somatomedin A) 6FAM-CCCTCTACCGTCGCG
AACCCGA-BHQ-1
GAGCGGTTTCGGTGTCGTTA CCAACTCGATTTAAACCGACG
Neurogenin 1 6FAM-CGATAACGACCTCCC
GCGAACATAAA-BHQ-1
CGTGTAGCGTTCGGGTATTTGTA CGATAATTACGAACACACTCCGAAT
Runt-related transcription factor 3 6FAM-CGCACGAACTCGCC
TACGTAATCCG-BHQ-1
CGTTCGATGGTGGACGTGT GACGAACAACGTCTTATTACAACGC
Suppressor of cytokine signaling 1 6FAM-ACAATTCCGCTAAC
GACTATCGCGCA-BHQ-1
GCGTCGAGTTCGTGGGTATTT CCGAAACCATCTTCACGCTAA
ALU 6FAM-CCTACCTTAACCTCCC-
MGBNFQ
GGTTAGGTATAGTGGTTTATATT
TGTAATTTTAGTA
ATTAACTAAACTAATCTTAAACTCCT
AACCTCA
All sequences are provided 5′ to 3′.
Figure W1. Fold change of RECQ helicase mRNA expression with-
out normalization for proliferation using PCNA mRNA expression
(CRC/normal colon). Solid horizontal lines indicate the median fold
change for each RECQ helicase. The dashed horizontal line indi-
cates a fold change level of 1, where the expression level of the
RECQhelicase in the tumor is equal to the expression level in normal
colonic mucosa. WRN (P = .0259), BLM (P < .0001), RECQL (P <
.0183), and RECQL4 (P < .001) expression levels are significantly
increased in tumor compared to normal mucosa. There is no sig-
nificant difference in RECQL5mRNA expression in tumor compared
to normal colonic mucosa (P = .182). Asterisks indicate statistical
significance in the fold change compared to the theoretical mean
of 1 for the indicated helicases.
Figure W2. ROC curves for RECQ helicase expression in CRC and normal colonic mucosa. The area under the curve and 95% confi-
dence intervals for each ROC analysis are given as follows: WRN, 0.7136 (0.6067-0.8205); BLM, 0.6101 (0.4940-0.7262); RECQL, 0.6994
(0.5920-0.8069); RECQL4 (0.5103-0.7402); RECQL5 (0.6236-0.8329). Dashed line is the line of identity.
Figure W3. Analysis of RECQ helicase expression by CRC stage. (A) RECQ helicase mRNA expression. There is a significant difference
in fold change of WRN expression in the CRCs compared to normal mucosa by stage (P = .0498); however, after all-pairwise post-hoc
comparisons, there was not enough power to detect differences among the stages. The highest median expression is seen in stage II
CRC. Higher expression levels of WRN in stage II compared to lower expression levels of WRN in the other tumor stages (compared to
matched normal mucosa) can be appreciated. However, no statistical significance is seen in the expression of BLM (P = .2193), RECQL4
(P = .4077), RECQL (P = .5992), or RECQL5 (P = .3889) in the CRCs compared to matched normal tissue in any of the stages. (B) RECQ
helicase IHC. On the basis of Allred scores, there is no statistically significant difference in expression of the RECQ helicases in CRCs across
stages, WRN (P = .5709), BLM (P = .3644), RECQL4 (P = .5451), RECQL (P = .1922), or RECQL5 (P = .5604).
Table W4. Somatic RECQL Mutations Identified by TCGA in CRCs and Their Predicted Impact.
RECQL AA
Mutation Mutation Type Mutation Assessor Polyphen-2 Exome Variant
A248T Missense Neutral Benign No
N397K Missense Medium Probably damaging No
S568L Missense Medium Probably damaging No
V41* Frameshift – – –
These predictions were obtained using Mutation Assessor v.2 and PolyPhen-2 HumVar algorithm.
The following web resources were used: Mutation Assessor, http://mutationassessor.org; PolyPhen-2,
http://genetics.bwh.harvard.edu/pph2; Exome Variant, http://evs.gs.washington.edu/EVS.
*Signifies deletion (caused by the frameshift mutation).
Table W5. Somatic RECQL5Mutations Identified by TCGA in CRCs and Their Predicted Impact.
RecQL5 AA
Mutation Mutation Type Mutation Assessor Polyphen-2 Exome Variant
E573D Missense Neutral Benign No
L556I Missense Low Benign No
C832Y Missense Low Benign No
E980K Missense Medium Possibly damaging No
G71C Missense Medium Probably damaging No
T316I Missense High Probably damaging No
These predictions were obtained using Mutation Assessor v.2 and PolyPhen-2 HumVar algorithm.
The following web resources were used: Mutation Assessor, http://mutationassessor.org; PolyPhen-2,
http://genetics.bwh.harvard.edu/pph2; Exome Variant, http://evs.gs.washington.edu/EVS.
Table W2. Somatic BLM Mutations Identified by TCGA in CRCs and Their Predicted Impact.
BLM AA
Mutation Mutation Type Mutation Assessor PolyPhen-2 Exome Variant
L647I Missense Low Benign No
A964T Missense Low Benign No
F1087C Missense Low Benign No
S1252F Missense Low Possibly damaging No
S147Y Missense Medium Probably damaging No
Y784C Missense Medium Possibly damaging No
R1144I Missense Medium Possibly damaging No
A703V Missense High Probably damaging No
Y764C Missense High Probably damaging No
HPfs (3518) Frameshift – – –
HPfs (3811) Frameshift – – –
These predictions were obtained using Mutation Assessor v.2 and PolyPhen-2 HumVar algorithm.
The following web resources were used: Mutation Assessor, http://mutationassessor.org; PolyPhen-2,
http://genetics.bwh.harvard.edu/pph2; Exome Variant, http://evs.gs.washington.edu/EVS.
Table W3. Somatic WRN Mutations Identified by TCGA in CRCs and Their Predicted Impact.
BLM AA
Mutation Mutation Type Mutation Assessor PolyPhen-2 Exome Variant
L647I Missense Low Benign No
A964T Missense Low Benign No
F1087C Missense Low Benign No
S1252F Missense Low Possibly damaging No
S147Y Missense Medium Probably damaging No
Y784C Missense Medium Possibly damaging No
R1144I Missense Medium Possibly damaging No
A703V Missense High Probably damaging No
Y764C Missense High Probably damaging No
HPfs (3518) Frameshift – – –
HPfs (3811) Frameshift – – –
These predictions were obtained using Mutation Assessor v.2 and PolyPhen-2 HumVar algorithm.
The following web resources were used: Mutation Assessor, http://mutationassessor.org; PolyPhen-2,
http://genetics.bwh.harvard.edu/pph2; Exome Variant, http://evs.gs.washington.edu/EVS.
